

REGENERON PHARMACEUTICALS INC.

ISIN: US75886F1075 WKN: 75886F107

Přehled

14.08.2024 16:31:09

Cena

1.155,6492 USD

Změna



7,16% (77,18)

Základní údaje

| | |
|---------------------------|---------------------------------------|
| ISIN | US75886F1075 |
| Symbol | REGN |
| Burza | London Stock Exchange |
| Měna | USD |
| Sektor | Chemical / Pharmaceutical / Health |
| Typ cenného papíru | Akcie |
| Tržní kapitalizace (mil.) | 116.169 EUR |
| Benchmark | S&P 500 |

Tržní data

| | |
|----------------------------------|--------------------|
| Nákup (částka) | - |
| Prodej (částka) | - |
| Otevírací cena | 1.155,6492 USD |
| Max | 1.155,6492 USD |
| Min | 1.155,6492 USD |
| Závěrečná cena (předchozí den) | 1.078,4689 USD |
| Cena vážená obchodovaným objemem | 1.155,64922 USD |
| Objem (kusy) | 475 |
| Obchodovaný objem | 548.933,38 |
| Počet obchodů | 1 |
| Poslední zobchodovaný počet | 475 |

Futures a opce

| | |
|---------------------|---|
| Související Futures | - |
| Související Opce | - |

51



Minulá výkonnost nezaručuje výkonnost budoucí.

Zdroj: FactSet

Analýzy a prognózy

| Sektory | Z trhů | | |
|------------|--------|-----------------------|----------|
| Datum | | Nadpis | Stáhnout |
| 12.08.2024 | | Global Equity Ratings | |
| 24.07.2024 | | Global Equity Ratings | |
| 12.07.2024 | | Global Equity Ratings | |
| 21.06.2024 | | Global Equity Ratings | |
| 14.06.2024 | | Global Equity Ratings | |

PDF ke stažení

Report společnosti: REGENERON
PHARMACEUTICALS INC.



Detaily

14.08.2024 16:31:09

Cena

1.155,6492 USD

Změna ▲ 7,16% (77,18)

Základní údaje

ISIN US75886F1075

Symbol REGN

Burza London Stock Exchange

Měna USD

Sektor Chemical /
Pharmaceutical / HealthTyp cenného
papíru AkcieTržní
kapitalizace
(mil.) 116.169 EUR

Benchmark S&P 500

Tržní data

Nákup (částka) -

Prodej (částka) -

Otevírací cena 1.155,6492
USDMax 1.155,6492
USDMin 1.155,6492
USDZávěrečná cena (předchozí
den) 1.078,4689
USDCena vážená
obchodovaným objemem 1.155,64922
USD

Objem (kusy) 475

Obchodovaný objem 548.933,38

Počet obchodů 1

Poslední zobchodovaný
počet 475

Výkonnost a riziko

| | 6m | 1r | 3r |
|----------------|------|------|------|
| Výkonn. (%) | - | - | - |
| Výkonn. (abs.) | - | - | - |
| Beta | 0,60 | 0,58 | 0,57 |
| Volatilita | 2,69 | 6,43 | 6,37 |

51



Minulá výkonnost nezaručuje výkonnost budoucí.

Zdroj: FactSet

Ceny

Ø cena 5 dní | Ø objem 5 dní (ks.) - USD (35)

Ø cena 30 dní | Ø objem 30 dní (ks.) 1.087,8696 USD (94)

Ø cena 100 dní | Ø objem 100 dní (ks.) 1.026,7107 USD (171)

Ø cena 250 dní | Ø objem 250 dní (ks.) 950,3891 USD (286)

YTD Max | datum 1.155,6492 USD (14.08.2024)

YTD Min | datum 895,3700 USD (09.01.2024)

52týdenní max. | datum 1.155,6492 USD (14.08.2024)

52týdenní min. | datum 825,2400 USD (06.09.2023)

Arbitrážní výhledy

| Burza | Datum | Čas | Cena | Obchodovaný objem (mil.) | Počet obchodů |
|-----------------------|------------|-------|----------------|--------------------------|---------------|
| Xetra | 20.10.2023 | 17:35 | 766,50 EUR | 0,09 | 18 |
| Vienna Stock Exchange | 21.08.2024 | 17:32 | 1.074,00 EUR | 0,00 | 5 |
| Tradegate | 21.08.2024 | 18:03 | 1.067,50 EUR | 0,12 | 22 |
| Stuttgart | 21.08.2024 | 15:11 | 1.080,00 EUR | 0,00 | 2 |
| Nasdaq | 21.08.2024 | 18:51 | 1.188,02 USD | 119,34 | 5.974 |
| Munich | 21.08.2024 | 08:04 | 1.075,00 EUR | 0,00 | 1 |
| London Stock Exchange | 14.08.2024 | 16:31 | 1.155,6492 USD | 0,55 | 1 |
| Hanover | 21.08.2024 | 08:01 | 1.068,50 EUR | 0,00 | 1 |

| | | | | | |
|--|------------|-------|--------------|------|---|
| Hamburg | 21.08.2024 | 14:30 | 1.093,00 EUR | 0,01 | 2 |
| Frankfurt | 21.08.2024 | 14:51 | 1.087,00 EUR | 0,01 | 3 |
| Euronext Milan MTF Trading After Hours | 26.06.2024 | 18:39 | 1.004,50 EUR | 0,00 | 1 |
| Euronext Milan MTF Global Equity Market | 21.08.2024 | 17:44 | 1.074,50 EUR | 0,02 | 4 |
| Duesseldorf | 21.08.2024 | 08:10 | 1.063,00 EUR | 0,00 | 1 |
| Berlin | 21.08.2024 | 08:04 | 1.067,50 EUR | 0,00 | 1 |

Profil společnosti

Logo společnosti

Kontakty

REGENERON PHARMACEUTICALS INC.

--

777 Old Saw Mill River Road - 10591-6707
Tarrytown

Telefon:+1-914-847-7000

Fax:+

E-mail:usinfo@regeneron.com

PDF ke stažení

Report společnosti: REGENERON
PHARMACEUTICALS INC. 

Profil společnosti

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Členové představenstva

| | |
|--------------------|--------------------------------|
| George Yancopoulos | Chairman of Board of Directors |
|--------------------|--------------------------------|

| | |
|----------------|------------------------------|
| Bonnie Bassler | Member of Board of Directors |
|----------------|------------------------------|

| | |
|----------------|------------------------------|
| Craig Thompson | Member of Board of Directors |
|----------------|------------------------------|

| | |
|-----------------|------------------------------|
| David Schenkein | Member of Board of Directors |
|-----------------|------------------------------|

| | |
|-------------|------------------------------|
| Huda Zoghbi | Member of Board of Directors |
|-------------|------------------------------|

| | |
|------------------|------------------------------|
| Joseph Goldstein | Member of Board of Directors |
|------------------|------------------------------|

| | |
|-----------------|------------------------------|
| Kathryn Guarini | Member of Board of Directors |
|-----------------|------------------------------|

| | |
|---------------|------------------------------|
| Michael Brown | Member of Board of Directors |
|---------------|------------------------------|

| | |
|----------|------------------------------|
| N. Coles | Member of Board of Directors |
|----------|------------------------------|

| | |
|-------------|------------------------------|
| Arthur Ryan | Member of Board of Directors |
|-------------|------------------------------|

| | |
|----------------|------------------------------|
| Christine Poon | Member of Board of Directors |
|----------------|------------------------------|

| | |
|-------------|------------------------------|
| George Sing | Member of Board of Directors |
|-------------|------------------------------|

| | |
|----------------------|----------------------------|
| Leonard S. Schleifer | Chairman of Managing Board |
|----------------------|----------------------------|

| | |
|-----------------------|-------------------------------|
| George D. Yancopoulos | Member of Executive Committee |
|-----------------------|-------------------------------|

| | |
|-------------|-------------------------------|
| Bob McCowan | Member of Executive Committee |
|-------------|-------------------------------|

| | |
|------------------|-------------------------------|
| Joseph J. LaRosa | Member of Executive Committee |
|------------------|-------------------------------|

| | |
|----------------|-------------------------------|
| Marion McCourt | Member of Executive Committee |
|----------------|-------------------------------|

| | |
|----------------|-------------------------------|
| Melissa Lozner | Member of Executive Committee |
|----------------|-------------------------------|

| | |
|------------------|-------------------------------|
| Robert E. Landry | Member of Executive Committee |
|------------------|-------------------------------|

| | |
|----------------|-------------------------------|
| Sally A. Paull | Member of Executive Committee |
|----------------|-------------------------------|

Smita Pillai

Member of Executive
Committee